Compassionate Use of Remdesivir for Patients with Severe Covid-19

被引：1788

作者：

Grein, J. ^{[1
]}

Ohmagari, N. ^{[10
]}

Shin, D. ^{[2
]}

Diaz, G. ^{[16
]}

Asperges, E. ^{[19
]}

Castagna, A. ^{[20
]}

Feldt, T. ^{[26
]}

Green, G. ^{[3
]}

Green, M. L. ^{[17
]}

Lescure, F-X ^{[27
,28
]}

Nicastri, E. ^{[22
]}

Oda, R. ^{[11
]}

Yo, K. ^{[12
]}

Quiros-Roldan, E. ^{[23
]}

Studemeister, A. ^{[4
]}

Redinski, J. ^{[4
]}

Ahmed, S. ^{[31
]}

Bernett, J. ^{[6
]}

Chelliah, D. ^{[2
]}

Chen, D. ^{[32
]}

Chihara, S. ^{[18
]}

Cohen, S. H. ^{[7
]}

Cunningham, J. ^{[33
]}

Monforte, A. DArminio ^{[21
]}

Ismail, S. ^{[8
]}

Kato, H. ^{[13
]}

Lapadula, G. ^{[24
]}

L'Her, E. ^{[29
]}

Maeno, T. ^{[14
]}

Majumder, S. ^{[5
]}

Massari, M. ^{[25
]}

Mora-Rillo, M. ^{[34
]}

Mutoh, Y. ^{[15
]}

Nguyen, D. ^{[30
]}

Verweij, E. ^{[35
]}

Zoufaly, A. ^{[36
]}

Osinusi, A. O. ^{[9
]}

DeZure, A. ^{[9
]}

Zhao, Y. ^{[9
]}

Zhong, L. ^{[9
]}

Chokkalingam, A. ^{[9
]}

Elboudwarej, E. ^{[9
]}

Telep, L. ^{[9
]}

Timbs, L. ^{[9
]}

Henne, I ^{[9
]}

Sellers, S. ^{[9
]}

Cao, H. ^{[9
]}

Tan, S. K. ^{[9
]}

Winterbourne, L. ^{[9
]}

Desai, P. ^{[9
]}

机构：

[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[2] El Camino Hosp, Mountain View, CA USA

[3] Sutter Santa Rosa Reg Hosp, Santa Rosa, CA USA

[4] Reg Med Ctr, San Jose, CA USA

[5] Good Samaritan Hosp, San Jose, CA USA

[6] John Muir Hlth, Walnut Creek, CA USA

[7] UC Davis Hlth, Sacramento, CA USA

[8] NorthBay Med Ctr, Fairfield, CA USA

[9] Gilead Sci, 333 Lakeside Dr, Foster City, CA 94404 USA

[10] Natl Ctr Global Hlth & Med, Tokyo, Japan

[11] Tokyo Bay Urayasu Ichikawa Med Ctr, Urayasu, Japan

[12] Hiratsuka City Hosp, Hiratsuka, Kanagawa, Japan

[13] Yokohama City Univ Med, Yokohama, Kanagawa, Japan

[14] Gunma Univ Hosp, Gunma, Japan

[15] Tosei Gen Hosp, Seto, Japan

[16] Providence Reg Med Ctr Everett, Everett, WA USA

[17] Univ Washington, Med Ctr Northwest, Seattle, WA 98195 USA

[18] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[19] Fdn IRCCS Policlin San Mateo, Pavia, Italy

[20] Ist Sci San Raffaele, IRCCS, Milan, Italy

[21] Univ Milan, Dept Hlth Serv, Azienda Socio Sanit Terr Spedali ASST Santi Paolo, Milan, Italy

[22] IRCCS L Spallanzani, Natl Inst Infect Dis, Rome, Italy

[23] Univ Brescia, ASST Civili Brescia, Brescia, Italy

[24] Univ Milano Bicocca, San Gerardo Hosp, ASST Monza, Monza, Italy

[25] Azienda Unite Sanit Locali IRCCS, Reggio Emilia, Italy

[26] Univ Klinikum Dusseldorf, Dusseldorf, Germany

[27] Univ Paris, Infect Antimicrobiens Modelisat Evolut IAME, INSERM, Paris, France

[28] Hop Xavier Bichat, AP HP, Dept Infect Dis, Paris, France

[29] Ctr Hosp Reg & Univ Brest La Cavale Blanche, Brest, France

[30] Univ Hosp Bordeaux, Div Infect Dis & Trop Med, Bordeaux, France

[31] St Alexius Med Ctr, Hoffman Estates, IL USA

[32] Mackenzie Hlth, Richmond Hill, ON, Canada

[33] Columbia Univ, Irving Med Ctr, New York, NY USA

[34] Hosp Univ La Paz Carlos III, Inst Invest Hosp Univ La Paz, Madrid, Spain

[35] Bernhoven Hosp, Uden, Netherlands

[36] Kaiser Franz Josef Hosp, Vienna, Austria

[37] US Publ Hlth Serv Commissioned Corps, Washington, DC USA

[38] Miriam Hosp, Providence, RI 02906 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 24期

关键词：

CORONAVIRUS;

D O I：

10.1056/NEJMoa2007016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days. Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Results Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. Conclusions In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)

引用

页码：2327 / 2336

页数：10

共 50 条

[21] Remdesivir for Patients with COVID-19
Augustin, M.
Hallek, M.
Nitschmann, S.
[J]. INTERNIST, 2020, 61 (08): : 869 - 872
[22] Compassionate use of hzVSF-v13 in two patients with severe COVID-19
Kang, Chang Kyung
Choe, Pyoeng Gyun
Park, Sungman
Kim, Taek Soo
Seong, Moon-Woo
Kim, Nam-Joong
Oh, Myoung-don
Park, Wan Beom
Kim, Yoon-Won
[J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2371 - 2373
[23] Remdesivir in Severe Cases of COVID-19 Infection
Boretti, Alberto
[J]. CURRENT ORGANOCATALYSIS, 2024, 11 (04) : 273 - 278
[24] Remdesivir, a remedy or a ripple in severe COVID-19?
Doggrell, Sheila A.
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (11) : 1195 - 1198
[25] A practical approach for the compassionate use of convalescent plasma in patients with severe COVID-19 in developing countries
Sabando Velez, Brenner Elias
Plaza Meneses, Carlos
Felix, Miguel
Vanegas, Emanuel
Mata, Valeria L.
Romero Castillo, Horacio
Oliveros Alvear, Jorge W.
Bolona, Enrique
Alejandra Posligua, Maria
Layedra Bardi, Luis Renato
Vera Paz, Carlos
Cherrez-Ojeda, Ivan
[J]. JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2020, 14 (07): : 737 - 741
[26] USE OF REMDESIVIR AMONG HOSPITALIZED PATIENTS WITH SEVERE COVID-19: ANALYSIS OF ELECTRONIC HEALTH RECORDS FROM TRINETX COVID-19 NETWORK
Wolde, F.
Gressler, L.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S330 - S330
[27] The safety of remdesivir for COVID-19 patients
Chen, Hsien-Lin
Chao, Chien-Ming
Lai, Chih-Cheng
[J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (04) : 1910 - 1912
[28] Remdesivir in hospitalized COVID-19 Patients
Thiem, Helena
[J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (03): : 111 - +
[29] Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection
Sabers, Andrew J.
Williams, Amber L.
Farley, T. Michael
[J]. BMJ CASE REPORTS, 2020, 13 (10)
[30] Compassionate Use of Remdesivir in Pregnancy: A Case Series From a COVID-19 Dedicated Center and Review of Literature
Sharma, Priyanka
Gupta, Priyanka
Virmani, Rashmi
Pandey, Anil
Sharma, Jagadish C.
Sarkar, Avir
[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)

← 1 2 3 4 5 →